16 research outputs found
Genetic analyses of the QT interval and its components in over 250K individuals identifies new loci and pathways affecting ventricular depolarization and repolarization
Get PDFCorrelations in pravastatin treatment effect between carotid and femoral intima-media thickness, and coronary artery stenosis
No full textThe cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome A prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy
Get PDFAbstractObjectivesOn the basis of quantitative coronary angiography data, the cholesteryl ester transfer protein (CETP) TaqIB gene polymorphism has been postulated to predict the progression of coronary atherosclerosis and response to cholesterol-lowering therapy.BackgroundCholesteryl ester transfer protein mediates the exchange of lipids between anti-atherogenic high-density lipoprotein (HDL) and atherogenic apolipoprotein B containing lipoproteins and therefore plays a key role in human lipid metabolism. Hence, CETP gene polymorphisms may alter susceptibility to atherosclerosis.MethodsTo investigate the significance of the CETP TaqIB gene polymorphism with respect to clinical end points, we used the Cholesterol And Recurrent Events (CARE) cohort. The CARE study was designed to investigate the effect of five years of pravastatin therapy on coronary events.ResultsWe found that the odds ratios for the primary end point were not significantly different from unity for the three genetic subgroups after five years of placebo treatment. Furthermore, pravastatin induced similar changes in total cholesterol, low-density lipoprotein cholesterol, and HDL cholesterol among TaqIB genotypes, and both nonfatal myocardial infarction and deaths from coronary heart disease were reduced to the same extent in all three genotypes.ConclusionsIn the CARE cohort, the CETP TaqIB polymorphism does not predict cardiovascular events or discriminate between those who will or will not benefit from pravastatin treatment
The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome
No full textAlirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trialâ€
No full textB-Mode Ultrasound Assessment of Pravastatin Treatment Effect on Carotid and Femoral Artery Walls and Its Correlations With Coronary Arteriographic Findings: A Report of the Regression Growth Evaluation Statin Study (REGRESS)
No full textAdditional file 7: of Blood lipids influence DNA methylation in circulating cells
No full textThe HDL-C PS is nominally associated with confounder neutrophil counts. (CSV 202 bytes
Additional file 11: of Blood lipids influence DNA methylation in circulating cells
No full textEffect of lipid levels on DNA methylation corrected for nearest PS SNP within 1Ă‚ Mb. Estimate is the percentage change in DNA methylation per standard deviation change in lipid levels. (CSV 289 bytes
Additional file 10: of Blood lipids influence DNA methylation in circulating cells
No full textPower calculations were performed for the situations where the EWAS effect size estimate is (1) the true causal effect size, (2) half the true causal effect size, and (3) double the true causal effect size. (CSV 1Ă‚ kb
Additional file 5: of Blood lipids influence DNA methylation in circulating cells
No full textThe lipid-associated SNPs used to construct the polygenic scores. (CSV 1Ă‚ kb
